Loading…
← CockpitCompetitor Analysis › BLUEJET.NS Blue Jet HealthcareOpen in the cockpit ↗

Blue Jet HealthcareBLUEJET.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Manufactures specialty pharmaceutical intermediates, mainly for contrast media (imaging agents) and high-intensity sweeteners.

≈ A niche pharma-intermediate/specialty-chemical makerMomentum neutral 54
Mkt cap
$1.05B
US dollars, full cap
Free float
27%
of shares outstanding
$/day
$5.98M
20-day average traded
Fwd P/E
30.6×
forward earnings
ROIC−WACC
-1.5 pp
WACC 18.9%
Hurdle
+27 pp
Req g minus delivered
Next earnings
83 days
9 Feb 2027
Close · INR₹518.45
1D+1.5%
1W-3.2%
1M+2.2%
3M-14.6%
6M+18.6%
YTD-2.2%
1Y-10.8%
ATR %4.5%
Beta1.39
52w lowhigh20.0% off high

What Blue Jet Healthcare does

Manufactures specialty pharmaceutical intermediates, mainly for contrast media (imaging agents) and high-intensity sweeteners.

Supplies intermediates, the chemical building blocks, to a small group of global contrast-media makers under long relationships, so sales rest on a few buyers and on their production plans. Saccharin and custom-synthesis work add variety, and contrast-media volumes follow imaging procedures worldwide.

In one line: A niche pharma-intermediate/specialty-chemical maker.

Products and services

  • Contrast media intermediates
  • Saccharin/sweetener intermediates
  • CDMO/custom synthesis

Customers

  • Global contrast media manufacturers
  • Sweetener/food ingredient makers

Where it sits in the supply chain

  • Chemical synthesis
  • Intermediate manufacturing
  • Sale to global pharma/food-ingredient…

What could go right

  • Global imaging/contrast media demand growth
  • Capacity expansion

What could go wrong

  • Customer concentration
  • Raw material (iodine) price volatility

Moat: narrow (process know-how, customer qualification). Specialized iodine chemistry and long-qualified supply relationships with global contrast media makers.

Headquarters: Mumbai, India · Founded: 1968 · Employees: 581

Named competitors

Blue Jet Healthcare at a glance

Size Blue Jet Healthcare (BLUEJET.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.05B, the 583rd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹518.45 on 18 Nov 2026.

Performance Over six months the shares gained 18.6%, against -10.6% for the median peer and +3.8% for the India market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue fell 7.0% over the last twelve months (peer median +3.1%); the operating margin is 28.2% (peer median 8.7%).

Valuation It trades at 30.6× forward earnings against a peer median of 14.5× (2nd most expensive of 15).

Price implies For today's price to make sense, revenue must grow about 41% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is +27 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.5 points below its cost of capital (18.9% WACC).

Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026BLUEJET.NS 118Peer median 92
Six months, rebased to 100: Blue Jet Healthcare against the median of its 20 peers (local-currency closes).

Blue Jet Healthcare financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹11.0B₹9.42B₹10.2B₹7.08B₹7.18B
Revenue growth—-8%+45%-1%—
Gross profit₹4.66B₹3.62B₹4.41B₹2.77B₹2.70B
EBITDA₹3.35B₹2.96B₹3.79B₹2.35B₹2.21B
Net income₹2.85B₹2.48B₹3.05B₹1.64B₹1.60B
Free cash flown/a₹1.19B-₹289M₹674M₹823M
Capital expendituren/a₹2.19B₹799M₹1.74B₹593M
Total debt₹385M₹437M₹215M₹31.1M₹49.4M

Quarterly statements and history in the cockpit →

Blue Jet Healthcare competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%-20%-10%0%6007891952BSLNSVRA0027374553688513300497300702OMER6008120006504887MEDCLPYC688091605116688710VETO300119BLUEJET.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Blue Jet Healthcare is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%+200%20×40×60×1952BSLN0027374553688513300497300702000650605116688710BLUEJET.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Blue Jet Healthcare is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%600789BSLN0027374553300497300702600812000650605116688710VETO300119BLUEJET.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Blue Jet Healthcare is the large dot.

Blue Jet Healthcare competitors and peer comparison

Head to head with its named competitors (BLUEJET.NS vs NEULANDLAB.NS vs DIVISLAB.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Blue Jet Healthcare BLUEJET.NS$1.05B+19%-7%28%30.6×40.8%
Neuland Laboratories NEULANDLAB.NS$2.95B+28%+50%26%63.4×n/a
Divi's Laboratories DIVISLAB.NS$31.3B+60%+22%34%73.5×47.1%

How Blue Jet Healthcare compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Blue Jet Healthcare against its 20 peers (data as of 18 Nov 2026)
MeasureBLUEJET.NSPeer medianRank in peer set
1-month return+2.2%-5.9%4th highest of 21
6-month return+18.6%-10.6%5th highest of 21
Distance from 52-week high-20.0%-32.1%4th highest of 21
Revenue growth (TTM)-7.0%+3.1%4th lowest of 18
Operating margin28.2%8.7%highest of 19
Forward P/E30.6×14.5×2nd most expensive of 15
Growth the price implies (Req g, 7 yrs)40.8%1.0%most demanding of 14
Growth delivered (Del g)+13.8%+6.5%3rd highest of 14
Hurdle (Req g minus delivered)+27.0 pp-4.0 ppmost demanding of 14
ROIC minus cost of capital-1.5 pp+0.2 pp5th lowest of 19
EV / EBITDA26.4×7.3×most expensive of 5
Net debt / EBITDA-2.9×-1.3×least indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Blue Jet Healthcare BLUEJET.NSIndia$1.05B+19%-7%28%30.6×40.8%+13.8%
Shandong Lukang Pharmaceutical 600789.SSChina$1.05B-18%-7%3%n/a2.5%+6.5%
Everest Medicines 1952.HKHong Kong$1.05B-20%+193%-5%23.2×n/an/a
Basilea Pharmaceutica BSLN.SWSwitzerland$1.04B+33%+5%24%10.5×-5.6%+12.7%
Savara SVRAUnited States$1.04B-7%n/an/an/an/an/a
Sunflower Pharmaceutical 002737.SZChina$1.04B-11%+31%-7%4.7×-6.5%-7.7%
Towa Pharmaceutical 4553.TJapan$1.03B-10%+7%9%7.7×-0.3%+12.1%
Chengdu Easton Biopharmaceuticals 688513.SSChina$1.03B-33%-2%13%24.6×4.4%+7.7%
Jiangxi Fushine Pharmaceutical 300497.SZChina$1.02B-23%+103%24%9.9×7.5%-4.5%
Zhejiang Tianyu Pharmaceutical 300702.SZChina$1.02B+1%+27%4%21.4×4.3%+3.5%
Omeros OMERUnited States$1.08B+24%n/a-56%4.3×n/an/a
North China Pharmaceutical 600812.SSChina$1.08B-12%-21%5%n/a1.0%-4.2%
Renhe Pharmacy 000650.SZChina$1.01B-12%-7%14%16.9×-10.7%-7.0%
SAWAI 4887.TJapan$1.01B-18%+2%9%12.0×n/an/a
MedinCell MEDCL.PAFrance$1.09B+4%-23%-131%n/an/an/a
PYC Therapeutics PYC.AXAustralia$1.09B+29%n/an/an/an/an/a
Shanghai Yizhong Pharmaceutical 688091.SSChina$1.00B-49%+32%14%n/an/an/a
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%13.6×-2.0%+18.7%
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%59.3×12.7%+19.4%
Vetoquinol VETO.PAFrance$1.10B+19%-1%15%15.5×-3.6%+4.2%
Tianjin Ringpu Bio-technology 300119.SZChina$1.11B-7%-9%11%18.1×4.9%+11.3%

Questions

Who are Blue Jet Healthcare's main competitors?
Named competitors: Neuland Laboratories (NEULANDLAB.NS), Divi's Laboratories (DIVISLAB.NS). The cockpit's measured peer set (industry) also includes Shandong Lukang Pharmaceutical (600789.SS), Everest Medicines (1952.HK), Basilea Pharmaceutica (BSLN.SW), Savara (SVRA), Sunflower Pharmaceutical (002737.SZ), Towa Pharmaceutical (4553.T).
Is Blue Jet Healthcare expensive compared with its peers?
On forward p/e it trades at 30.6× against a peer median of 14.5×, 2nd most expensive of 15 in its peer set. For today's price to make sense, revenue must grow about 41% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is +27 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Blue Jet Healthcare stock performed?
Over six months to 18 Nov 2026 the shares returned +18.6% against -10.6% for the median peer; over one year -10.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.